Retatrutide, by Soma, represents a promising development in weight regulation. This dual-action drug combines incretin signaling activity with another receptor agonist engagement, indicating remarkable results in trial findings for body reduction . Scientists believe the drug could provide a alternative pathway for patients struggling with weight-r